BHCM
ALXO icon

Brevan Howard Capital Management’s ALX Oncology ALXO Stock Holding History

Brevan Howard Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159K Buy
+79,389
New +$151K ﹤0.01% 1949

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Brevan Howard Capital Management's ALXO Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in ALX Oncology (ALXO) in Q1 2026: 79,389 shares worth $159K. The stake represents ﹤0.01% of the portfolio and ranks #1949 among its holdings.

69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Brevan Howard Capital Management held 79,389 shares of ALX Oncology worth $159K as of Q1 2026.
  • ALX Oncology was a new Brevan Howard Capital Management position in Q1 2026.
  • ALX Oncology made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1949 holding.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.